Cara Therapeutics (CARA) Misses Q4 EPS by 3c
Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.43), $0.03 worse than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.43), $0.03 worse than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.